Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis

Cancer Immunology, Immunotherapy : CII
Ingrid M OveresHarry Dolstra

Abstract

CD8(+) T cells recognizing minor histocompatibility antigens (MiHA) on solid tumor cells may mediate effective graft-versus-tumor (GVT) reactivity after allogeneic stem cell transplantation (SCT). Previously, we identified LRH-1 as a hematopoietic-restricted MiHA encoded by the P2X5 gene. Here, we report that LRH-1 is aberrantly expressed on solid tumor cells. P2X5 mRNA expression is demonstrated in a significant portion of solid tumor cell lines, including renal cell carcinoma (RCC), melanoma, colorectal carcinoma, brain cancer and breast cancer. Importantly, P2X5 gene expression was also detected in a subset of primary solid tumor specimens derived from RCC, brain cancer and breast cancer patients. Furthermore, P2X5 expressing solid tumor cells can be effectively targeted by LRH-1-specific cytotoxic T lymphocytes under inflammatory conditions. The expression of HLA-B7 and CD54 on tumor cells increases upon cytokine stimulation resulting in improved T cell activation as observed by higher levels of degranulation and enhanced tumor cell lysis. Overall, hematopoietic-restricted MiHA LRH-1 is aberrantly expressed on solid tumor cells and may be used as target in GVT-specific immunotherapy after SCT.

References

Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N T UenoR E Champlin
May 18, 2001·Nature·F R Appelbaum
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniNicholas J Vogelzang
Apr 20, 2002·Transplantation·Nobuharu FujiiMine Harada
Jun 14, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Mikinori MiyazakiToshitada Takahashi
Apr 23, 2004·Trends in Immunology·Eric SpieringsEls Goulmy
Dec 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott S TykodiBrenda M Sandmaier
Oct 18, 2005·Nature Medicine·Marie-Christine MeunierClaude Perreault
Nov 3, 2005·Nature Clinical Practice. Oncology·Manit AryaHitendra R H Patel
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John A FoekensYixin Wang
Oct 26, 2006·Nature Reviews. Immunology·Gavin P DunnRobert D Schreiber
May 25, 2007·Cancer Science·Yoshiki AkatsukaToshitada Takahashi
Apr 10, 2008·Journal of Neuro-oncology·Joannes F M JacobsGosse J Adema
Apr 16, 2008·British Journal of Haematology·Ingrid M OveresHarry Dolstra

❮ Previous
Next ❯

Citations

Jun 29, 2011·Expert Review of Anticancer Therapy·Marco BregniUNKNOWN Solid Tumor Working Party of EBMT
Mar 23, 2011·Expert Opinion on Biological Therapy·Scott S TykodiJohn A Thompson
Jan 28, 2014·British Journal of Pharmacology·I AzimiG R Monteith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Brain Stem Neoplasms

Brain Stem Neoplasms are cancers that are common in children and can occur in the mesencephalon, pons or medulla oblongata. Discover the latest research on Brain Stem Neoplasms here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.